申请人:Glaxo Wellcome Inc.
公开号:US06350747B1
公开(公告)日:2002-02-26
The present invention relates generally to novel amine substituted oxindole compounds and compositions. Such compounds and compositions have utility as pharmacological agents in treating diseases or conditions alleviated by the inhibition or antagonism of protein kinase activated signalling pathways in general, and in particular in the pathological processes which involve aberrant cellular proliferation, such as tumor growth. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit protein tyrosine kinase and protein serine/threonine kinase inhibition, and which are useful in inhibiting tumor growth via inhibition of tumor-related angiogenesis.
本发明一般涉及新型胺取代的噁二酮化合物和组合物。这些化合物和组合物作为药理学药剂在治疗由于一般蛋白激酶激活的信号通路的抑制或拮抗而减轻的疾病或症状方面具有实用性,特别是在涉及异常细胞增殖的病理过程中,如肿瘤生长。具体而言,本发明涉及一系列取代的噁二酮化合物,其表现出蛋白酪氨酸激酶和蛋白丝氨酸/苏氨酸激酶抑制作用,并且在通过抑制与肿瘤相关的血管生成抑制肿瘤生长方面是有用的。